ArticleJournal of managed care & specialty pharmacy2022

Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.

Nick Jovanoski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.